Hypertension is one of the most important preventable causes of premature death worldwide. Although lowering of blood pressure by anti- hypertensive agents have been shown to reduce morbidity and mortality in major clinical trials, the optimal antihypertensive agent remains unclear. The recently completed and published Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)1 was the largest trial of antihypertensive therapy ever conducted. ALLHAT is also the first clinical trial that designed to compare different antihypertensive agents for prevention of coronary heart disease (CHD) with the combined incidence of fatal CHD and non-fatal myocardial infarction as the primary endpoint. Since the publication of the results of ALLHAT, there has been intense debate across the medical community about its implications. What is the clinical implication of the results of ALLHAT on our clinical practice in treating patients with hypertension, and are their findings applicable to the local Chinese population?
Raymond Kin-Man Miu, Chu-Pak Lau, Hung-Fat Tse, ALLHAT: More Answers or Questions? Journal of the Hong Kong College of Cardiology 2003;11(3) https://doi.org/10.55503/2790-6744.1154